Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 1

Status

Completed 3Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 7OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Head & Neck 3Sarcoma 1Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Lymphoid Interstitial Pneumonia 1Lip Neoplasms 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Carcinoma, Squamous Cell 1Carcinoma 1

Interventions

Cyclophosphamide 2067Radiotherapy 1990Cisplatin 1856Carboplatin 1560Gemcitabine 1454Paclitaxel 1320Bevacizumab 1320pembrolizumab 1237Docetaxel 1227Oxaliplatin 1184Capecitabine 1176Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 971Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 898Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 639Lenalidomide 618Biopsy 594fludarabine phosphate 569

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × ficlatuzumab × Clear all
NCT03422536 2024-09-04

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

University of Arizona

Phase 2 Completed
78 enrolled 16 charts
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03316599 2021-08-03

Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

Dana-Farber Cancer Institute

Phase 1 Completed
26 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02109627 2020-03-24

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

University of California, San Francisco

Phase 1 Terminated
17 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02277197 2019-04-18

Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

University of Pittsburgh

Phase 1 Completed
14 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02277184 2017-11-13

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

University of Pittsburgh

Phase 1 Terminated
1 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma

NCT01189513 2012-02-20

SCH-900105 in Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 1 Withdrawn
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡